NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $0.48 0.00 (-0.84%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytosorbents Stock (NASDAQ:CTSO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytosorbents alerts:Sign Up Key Stats Today's Range$0.45▼$0.5350-Day Range$0.48▼$0.8152-Week Range$0.45▼$1.39Volume171,818 shsAverage Volume70,548 shsMarket Capitalization$29.83 millionP/E RatioN/ADividend YieldN/APrice Target$5.38Consensus RatingHold Company Overview Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure. CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units. Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.AI Generated. May Contain Errors. Read More Cytosorbents Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 41% of companies evaluated by MarketBeat, and ranked 685th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCytosorbents has a consensus price target of $5.38, representing about 1,022.1% upside from its current price of $0.48.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.19) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.49% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 47.19, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently decreased by 0.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentCytosorbents has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cytosorbents this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by Insiders6.60% of the stock of Cytosorbents is held by insiders.Percentage Held by Institutions32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTSO Stock News HeadlinesHC Wainwright Comments on Cytosorbents Q1 EarningsMay 18 at 2:21 AM | americanbankingnews.comTranscript: CytoSorbents Q1 2026 Earnings Conference CallMay 15, 2026 | finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 19 at 1:00 AM | American Alternative (Ad)CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...May 14, 2026 | uk.finance.yahoo.comCytosorbents Corporation (CTSO) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comCytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory UpdateMay 13, 2026 | prnewswire.comCytosorbents (CTSO) to Release Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comCytoSorbents to Report First Quarter 2026 Financial Results and Recent Business HighlightsApril 30, 2026 | prnewswire.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $0.6392 at the start of the year. Since then, CTSO shares have decreased by 25.1% and is now trading at $0.4790. How were Cytosorbents' earnings last quarter? Cytosorbents Corporation (NASDAQ:CTSO) announced its quarterly earnings results on Wednesday, May, 13th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.02. The medical research company had revenue of $8.86 million for the quarter, compared to the consensus estimate of $9.40 million. Cytosorbents had a negative net margin of 31.85% and a negative trailing twelve-month return on equity of 235.57%. Read the conference call transcript. Who are Cytosorbents' major shareholders? Top institutional investors of Cytosorbents include Skylands Capital LLC (2.72%). Insiders that own company stock include Alan D Sobel, Michael G Bator and Kathleen P Bloch. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU). Company Calendar Last Earnings5/13/2026Today5/19/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CTSO's financial health is in the Red zone, according to TradeSmith. CTSO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year Founded2002Price Target and Rating Average Price Target for Cytosorbents$5.38 High Price Target$10.00 Low Price Target$0.75 Potential Upside/Downside+1,031.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.20 million Net Margins-31.85% Pretax Margin-32.93% Return on Equity-235.57% Return on Assets-37.88% Debt Debt-to-Equity Ratio4.70 Current Ratio1.09 Quick Ratio0.81 Sales & Book Value Annual Sales$37.20 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book5.28Miscellaneous Outstanding Shares62,795,000Free Float58,651,000Market Cap$29.83 million OptionableOptionable Beta1.43 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CTSO) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
